Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Operations (2018 - 2025)

10x Genomics (TXG) has disclosed Cash from Operations for 8 consecutive years, with 40777000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 704.28% to 40777000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 136050000.0 through Dec 2025, up 1941.57% year-over-year, with the annual reading at 136050000.0 for FY2025, 1941.57% up from the prior year.
  • Cash from Operations hit 40777000.0 in Q4 2025 for 10x Genomics, down from 43214000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 43214000.0 in Q3 2025 to a low of 26216000.0 in Q3 2021.
  • Historically, Cash from Operations has averaged 3626900.0 across 5 years, with a median of 481000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: crashed 643.69% in 2022 and later surged 704.28% in 2025.
  • Year by year, Cash from Operations stood at 5805000.0 in 2021, then skyrocketed by 136.4% to 13723000.0 in 2022, then skyrocketed by 87.7% to 25758000.0 in 2023, then plummeted by 126.2% to 6748000.0 in 2024, then soared by 704.28% to 40777000.0 in 2025.
  • Business Quant data shows Cash from Operations for TXG at 40777000.0 in Q4 2025, 43214000.0 in Q3 2025, and 17708000.0 in Q2 2025.